Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
New England Journal of Medicine, 2009 BACKGROUND The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. METHODS In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial ...
S. Rerks-Ngarm +23 more
semanticscholar +1 more source
HIV-1 enhances mTORC1 activity and repositions lysosomes to the periphery by co-opting Rag GTPases
Scientific Reports, 2017 HIV-1 co-opts several host machinery to generate a permissive environment for viral replication and transmission. In this work we reveal how HIV-1 impacts the host translation and intracellular vesicular trafficking machineries for protein synthesis and ...
Alessandro Cinti +8 more
doaj +1 more source
Depicting HIV-1 Transcriptional Mechanisms: A Summary of What We Know
Viruses, 2020 Despite the introduction of combinatory antiretroviral therapy (cART), HIV-1 infection cannot be cured and is still one of the major health issues worldwide. Indeed, as soon as cART is interrupted, a rapid rebound of viremia is observed.
Antoine Dutilleul +2 more
doaj +1 more source
Medicine, 2016 To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1 ...
Lola Falcón-Neyra +14 more
semanticscholar +1 more source
Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles [PDF]
, 2002 BACKGROUND: Cellulose acetate phthalate (CAP), a promising candidate microbicide for prevention of sexual transmission of the human immunodeficiency virus type 1 (HIV-1) and other sexually transmitted disease (STD) pathogens, was shown to inactivate HIV ...
A Nicholls +67 more
core +3 more sources
Identification of a New HIV-1 BC Intersubtype Circulating Recombinant Form (CRF108_BC) in Spain
Viruses, 2021 The extraordinary genetic variability of human immunodeficiency virus type 1 (HIV-1) group M has led to the identification of 10 subtypes, 102 circulating recombinant forms (CRFs) and numerous unique recombinant forms.
Javier E. Cañada +15 more
doaj +1 more source
Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load. [PDF]
, 2012 Chronic HIV-1 infection results in the expansion of both NKG2C+ and CD16+CD56- human natural killer cells. NKG2C+ cells proliferate in response to human cytomegalovirus (HCMV) and expansion of the dysfunctional CD56-CD16+ natural killer (NK) cells is ...
Bower, Mark +5 more
core +1 more source
Hiding in plain sight – platelets, the silent carriers of HIV-1
Platelets, 2021 There are approximately 38 million people globally living with Human immunodeficiency virus 1 (HIV-1) and given the tremendous success of combination antiretroviral therapy (cART) this has dramatically reduced mortality and morbidity with prevention ...
Yvonne Baumer +11 more
doaj +1 more source
The Long Noncoding RNA HEAL Regulates HIV-1 Replication through Epigenetic Regulation of the HIV-1 Promoter. [PDF]
, 2019 A major challenge in finding a cure for HIV-1/AIDS is the difficulty in identifying and eradicating persistent reservoirs of replication-competent provirus.
Chang, Kungyen +11 more
core +1 more source
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
New England Journal of Medicine, 2021 BACKGROUND Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the ...
L. Corey +44 more
semanticscholar +1 more source